Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
280.76
+6.28 (+2.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
April 05, 2023
Via
Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
April 04, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
March 21, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Alnylam Pharmaceuticals's Return On Capital Employed Insights
February 27, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
February 24, 2023
Via
Benzinga
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
October 07, 2022
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
March 03, 2023
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Analyst Ratings for Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
October 03, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
December 16, 2022
Via
Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
November 02, 2022
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
November 02, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
October 27, 2022
Via
Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
October 27, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
October 13, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
October 13, 2022
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Where Alnylam Pharmaceuticals Stands With Analysts
October 03, 2022
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
September 20, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.